keyword
MENU ▼
Read by QxMD icon Read
search

Endometrioid carcinoma

keyword
https://www.readbyqxmd.com/read/28098854/lsd1-sustains-estrogen-driven-endometrial-carcinoma-cell-proliferation-through-the-pi3k-akt-pathway-via-di-demethylating-h3k9-of-cyclin%C3%A2-d1
#1
Chunqin Chen, Yanan Wang, Shiyu Wang, Yuan Liu, Jiawen Zhang, Yuyao Xu, Zhenbo Zhang, Wei Bao, Sufang Wu
A recent study reported that histone lysine specific demethylase 1 (LSD1, KDM1A) is overexpressed in endometrioid endometrial carcinoma (EEC) and associated with tumor progression as well as poor prognosis. However, the physiological function and mechanism of LSD1 in endometrial cancer (EC) remains largely unknown. In this study, we demonstrate that β-estradiol (E2) treatment increased LSD1 expression via the GPR30/PI3K/AKT pathway in endometrial cancer cells. Both siGPR30 and the PI3K inhibitor LY294002 block this effect...
January 16, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28088687/whole-genome-dna-methylation-profiling-identifies-epigenetic-signatures-of-uterine-carcinosarcoma
#2
Jing Li, Xiaoyun Xing, Daofeng Li, Bo Zhang, David G Mutch, Ian S Hagemann, Ting Wang
Uterine carcinosarcoma (UCS) is a form of endometrial cancer simultaneously exhibiting carcinomatous and sarcomatous elements, but the underlying molecular and epigenetic basis of this disease is poorly understood. We generated complete DNA methylomes for both the carcinomatous and the sarcomatous components of three UCS samples separated by laser capture microdissection and compared DNA methylomes of UCS with those of normal endometrium as well as methylomes derived from endometrioid carcinoma, serous endometrial carcinoma, and endometrial stromal sarcoma...
January 12, 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28079598/interobserver-agreement-in-endometrial-carcinoma-histotype-diagnosis-varies-depending-on-the-cancer-genome-atlas-tcga-based-molecular-subgroup
#3
Lien N Hoang, Mary A Kinloch, Joyce M Leo, Katherine Grondin, Cheng-Han Lee, Carol Ewanowich, Martin Köbel, Angela Cheng, Aline Talhouk, Melissa McConechy, David G Huntsman, Jessica N McAlpine, Robert A Soslow, C Blake Gilks
The Cancer Genome Atlas recently identified a genomic-based molecular classification of endometrial carcinomas, with 4 molecular categories: (1) ultramutated (polymerase epsilon [POLE] mutated), (2) hypermutated (microsatellite instability), (3) copy number abnormalities-low, and (4) copy number abnormalities-high. Two studies have since proposed models to classify endometrial carcinomas into 4 molecular subgroups, modeled after The Cancer Genome Atlas, using simplified and more clinically applicable surrogate methodologies...
February 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28069049/dedifferentiated-endometrioid-carcinoma-of-the-uterus-report-of-four-cases-and-review-of-literature
#4
Jiheun Han, Eun Young Ki, Sung Eun Rha, SooYoung Hur, Ahwon Lee
BACKGROUND: Dedifferentiated endometrioid adenocarcinoma (DEAC) is rare and is known to be more aggressive than high-grade endometrioid carcinoma. Differentiating between the two is important to provide appropriate treatment for patients. CASE PRESENTATION: This is a retrospective study including four cases of DEAC of the uterus, which was diagnosed and treated in our Obstetrics and Gynecology department between January 2013 and December 2015. Clinical, pathological, and immunohistochemical staining features are discussed...
January 10, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28068595/the-impact-of-lymphadenectomy-on-survival-endpoints-in-women-with-early-stage-uterine-endometrioid-carcinoma-a-matched-analysis
#5
Ahmed I Ghanem, Nadia T Khan, Meredith Mahan, Ahmed Ibrahim, Thomas Buekers, Mohamed A Elshaikh
OBJECTIVES: The role of pelvic lymphadenectomy (LA) in women with stage I endometrial carcinoma (EC) is controversial. The objective of this study is to investigate the prognostic impact of LA on survival endpoints in matched cohorts of women with stage I EC solely of endometrioid histology. Survival endpoints included recurrence-free (RFS), disease-specific (DSS) and overall survival (OS). METHODS AND MATERIALS: Patients with FIGO stage I EC who underwent hysterectomy with LA as part of their surgical staging between 1/1990 and 6/2015 were matched to a similar group that underwent hysterectomy without lymphadenectomy (NLA), based on stage, grade and adjuvant management...
December 28, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28062021/endometrioid-carcinoma-of-the-ovary-outcomes-compared-to-serous-carcinoma-after-10-years-of-follow-up
#6
Geneviève Bouchard-Fortier, Tony Panzarella, Barry Rosen, William Chapman, Lilian T Gien
OBJECTIVES: The prognostic significance of endometrioid ovarian cancer is unclear. In this study we compared rates of overall survival (OS) and disease-free survival between patients with endometrioid and serous ovarian cancers using long-term follow-up data. METHODS: We included patients with endometrioid or serous ovarian cancers diagnosed at a single regional cancer centre between 1988 and 2006. Data on baseline and treatment characteristics were collected retrospectively...
January 2017: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/28060139/is-older-age-a-real-adverse-prognostic-factor-in-women-with-early-stage-endometrial-carcinoma-a-matched-analysis
#7
Laura Haley, Charlotte Burmeister, Thomas Buekers, Mohamed A Elshaikh
OBJECTIVES: The aim of this study was to evaluate if older age alone negatively impacts survival endpoints in women with early-stage uterine endometrioid carcinoma (EC), or its reported prognostic impact is due to an interaction with other well-known adverse factors using matched-analysis methodology. METHODS: We identified 1254 patients with International Federation of Gynecology and Obstetrics stage I-II EC who underwent hysterectomy at our institution. We created 2 matched groups based on International Federation of Gynecology and Obstetrics stage, tumor grade, lymph node dissection status, and the type of adjuvant management...
January 4, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28059101/steroid-hormone-synthesis-by-the-ovarian-stroma-surrounding-epithelial-ovarian-tumors-a-potential-mechanism-in-ovarian-tumorigenesis
#8
Luis Z Blanco, Elisabetta Kuhn, Jane C Morrison, Asli Bahadirli-Talbott, Anne Smith-Sehdev, Robert J Kurman
Epithelial ovarian tumors are responsive to steroid hormone stimulation and the ovarian stroma may have a direct role in this process. We evaluated immunohistochemical markers of sex-steroid differentiation and steroidogenesis (calretinin, inhibin, steroidogenic factor 1), steroid enzymes involved in hormone biosynthesis (CYP17, CYP19, HSD17β1, AKR1C3), and hormone receptors (estrogen receptor, progesterone receptor, and androgen receptor) in 101 epithelial ovarian tumors and in normal structures implicated in ovarian carcinogenesis (ovarian surface epithelium and cortical inclusion cysts) in an attempt to elucidate this process...
January 6, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28049216/cancer-implications-for-patients-with-endometriosis
#9
Mary Ann Wilbur, Ie-Ming Shih, James H Segars, Amanda N Fader
Endometriosis is defined as the presence of viable endometrial glands and stroma outside of the uterus. It is a common disease, occurring in 5 to 15% of all women. Endometriosis is associated with chronic pelvic pain and infertility and often requires surgical intervention for definitive treatment. Although it is a benign gynecologic condition, endometriosis shares pathophysiologic features with cancer. In recent years, both histologic and epidemiologic evidence has accumulated, suggesting that ovarian endometriosis may give rise to malignant ovarian tumors, primarily those that are epithelial in origin, known as endometriosis-associated ovarian carcinoma (EAOC) including ovarian clear cell carcinoma, endometrioid carcinoma, and the least common, seromucinous tumors...
January 3, 2017: Seminars in Reproductive Medicine
https://www.readbyqxmd.com/read/28041971/clinicopathological-analysis-of-mixed-endometrial-carcinomas-clinical-relevance-of-different-neoplastic-components
#10
Esther Diana Rossi, Tommaso Bizzarro, Giorgia Monterossi, Frediano Inzani, Francesco Fanfani, Giovanni Scambia, Gian Franco Zannoni
Mixed endometrial carcinomas (MEC) refer to tumors characterized by 2 or more distinct histotypes mostly comprised of endometrioid (EC) and serous /clear cell carcinomas (SC/CC). The specific quantification of these distinct components represents a challenging and critical point for both prognosis and management. Herein, we analyze a large series of MEC and compare them with EC and SC/CC. We evaluated a series of 69 MEC between January 2002 and December 2015. We compared the MEC series with 186 EC (including 117 endometrioid G3), 31 SC and 38 CC...
December 29, 2016: Human Pathology
https://www.readbyqxmd.com/read/28002515/morphological-imaging-and-surgical-aspects-in-endometrial-endometrioid-adenocarcinoma
#11
Costin Berceanu, Alex Emilian Stepan, Claudia MehedinŢu, Monica Mihaela Cîrstoiu, Răzvan Ciortea, Sabina Berceanu, Ioana Andreea Gheonea, Elvira Brătilă
Endometrioid endometrial adenocarcinomas (EECs) are frequent genital tumors for which the clinical, imaging and histopathological integrated analysis is the basis of differential diagnosis and therapeutic attitude. This research represents a tertiary multicenter study including 58 cases examined histopathologically and immunohistochemically, surgically treated, on a five years period. The main characteristics of the patients in the study group are represented by the average age of 66 years, associated with obesity, hypertension, diabetes, history of infertility, early menopause, nulliparity or long-time oral contraception...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27997699/chromatin-remodelling-and-dna-repair-genes-are-frequently-mutated-in-endometrioid-endometrial-carcinoma
#12
Pablo García-Sanz, Juan Carlos Triviño, Alba Mota, María Pérez López, Eva Colás, Alejandro Rojo-Sebastián, Ángel García, Sonia Gatius, María Ruiz, Jaime Prat, Rafael López-López, Miguel Abal, Antonio Gil-Moreno, Jaume Reventós, Xavier Matias-Guiu, Gema Moreno-Bueno
In developed countries, endometrial carcinoma is the most common cancer that affects the female genital tract. Endometrial carcinoma is divided into two main histological types, type I or endometrioid and type II or non-endometrioid, each of which have characteristic, although not exclusive, molecular alterations and mutational profiles. Nevertheless, information about the implication and relevance of some of these genes in this disease is lacking. We sought here to identify new recurrently mutated genes in endometrioid cancers that play a role in tumourigenesis and that influence the clinical outcome...
December 20, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27993480/bokhman-redux-endometrial-cancer-types-in-the-21st-century
#13
Adrian A Suarez, Ashley S Felix, David E Cohn
In 1983 Jan V. Bokhman, M.D. published a landmark paper entitled "Two Pathogenetic Types of Endometrial Carcinoma" in which an enduring dualistic view of endometrial cancer was first proposed. "Type I" cancers are thought to represent estrogen driven mostly low grade endometrioid tumors strongly associated with obesity and other components of the metabolic syndrome. "Type II" cancers represent higher grade non-endometrioid tumors for which the latter associations are less significant. Basic tenets of this dichotomy including significant prognostic differences have been abundantly confirmed by later literature...
December 16, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27986878/nonsteroidal-anti-inflammatory-drugs-and-endometrial-carcinoma-mortality-and-recurrence
#14
Theodore M Brasky, Ashley S Felix, David E Cohn, D Scott McMeekin, David G Mutch, William T Creasman, Premal H Thaker, Joan L Walker, Richard G Moore, Shashikant B Lele, Saketh R Guntupalli, Levi S Downs, Christa I Nagel, John F Boggess, Michael L Pearl, Olga B Ioffe, Kay J Park, Shamshad Ali, Louise A Brinton
BACKGROUND: Recent data suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reductions in endometrial cancer risk, yet very few have examined whether their use is related to prognosis among endometrial cancer patients. METHODS: Study subjects comprised 4374 participants of the NRG Oncology/Gynecology Oncology Group 210 Study with endometrial carcinoma who completed a presurgical questionnaire that assessed history of regular prediagnostic NSAID use and endometrial cancer risk factors...
March 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/27984374/cd56-neural-cell-adhesion-molecule-expression-in-ovarian-carcinomas-association-with-high-grade-and-advanced-stage-but-not-with-neuroendocrine-differentiation
#15
Hans-Christian Bösmüller, Philipp Wagner, Deborah Lam Pham, Anna K Fischer, Karen Greif, Christine Beschorner, Bence Sipos, Falko Fend, Annette Staebler
OBJECTIVE: Neural cell adhesion molecule (CD56) has been proposed as a potential marker for neuroendocrine differentiation in carcinomas, together with synaptophysin and chromogranin A. However, CD56 immunoreactivity by itself can be found in a broad variety of tumors, including ovarian neoplasms. CD56 has recently been suggested as a potential target for antibody-based therapy. However, for ovarian carcinoma, there is only limited data available regarding the pattern of CD56 immunoreactivity, coexpression of neuroendocrine markers, and correlation with histological types and clinical parameters...
December 15, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27976698/epithelial-ovarian-carcinoma-diagnosis-by-desorption-electrospray-ionization-mass-spectrometry-imaging
#16
Maria Luisa Dória, James S McKenzie, Anna Mroz, David L Phelps, Abigail Speller, Francesca Rosini, Nicole Strittmatter, Ottmar Golf, Kirill Veselkov, Robert Brown, Sadaf Ghaem-Maghami, Zoltan Takats
Ovarian cancer is highly prevalent among European women, and is the leading cause of gynaecological cancer death. Current histopathological diagnoses of tumour severity are based on interpretation of, for example, immunohistochemical staining. Desorption electrospray mass spectrometry imaging (DESI-MSI) generates spatially resolved metabolic profiles of tissues and supports an objective investigation of tumour biology. In this study, various ovarian tissue types were analysed by DESI-MSI and co-registered with their corresponding haematoxylin and eosin (H&E) stained images...
December 15, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27956412/expression-of-renin-angiotensin-system-ras-components-in-endometrial-cancer
#17
Sarah J Delforce, Eugenie R Lumbers, Celine Corbisier de Meaultsart, Yu Wang, Anthony Proietto, Geoffrey Otton, Jim Scurry, Nicole M Verrills, Rodney J Scott, Kirsty G Pringle
A dysfunctional endometrial renin-angiotensin system (RAS) could aid the growth and spread of endometrial cancer. To determine if the RAS is altered in endometrial cancer, we measured RAS gene expression and protein levels in 30 human formalin-fixed, paraffin-embedded (FFPE) endometrioid carcinomas and their adjacent endometrium. All components of the RAS were expressed in most tumours and in adjacent endometrium; mRNA levels of (pro)renin receptor (ATP6AP2), angiotensin II type 1 receptor (AGTR1), angiotensin-converting enzyme (ACE1) and angiotensin-converting enzyme 2 (ACE2) mRNA levels were greater in tumour tissue than adjacent non-cancerous endometrium (P = 0...
January 2017: Endocrine Connections
https://www.readbyqxmd.com/read/27941362/molecular-characterization-of-endometrial-cancer-and-therapeutic-implications
#18
Locke Uppendahl, Sally A Mullany, Boris Winterhoff
PURPOSE OF REVIEW: This article reviews the emerging comprehensive genomic classification of endometrial carcinoma and discusses the therapeutic implications of these subgroups. RECENT FINDINGS: Comprehensive, multiplatform evaluation of endometrial cancers by the Cancer Genome Atlas stratified the molecular aberrations into four distinct subtypes: POLE mutations, microsatellite instability, copy-number low/microsatellite stable, and copy-number high/'serous-like...
February 2017: Current Opinion in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/27934879/xp11-2-translocation-renal-cell-carcinoma-with-nono-tfe3-gene-fusion-morphology-prognosis-and-potential-pitfall-in-detecting-tfe3-gene-rearrangement
#19
Qiu-Yuan Xia, Zhe Wang, Ni Chen, Hua-Lei Gan, Xiao-Dong Teng, Shan-Shan Shi, Xuan Wang, Xue Wei, Sheng-Bing Ye, Rui Li, Heng-Hui Ma, Zhen-Feng Lu, Xiao-Jun Zhou, Qiu Rao
Xp11 translocation renal cell carcinomas are characterized by several different translocations involving the TFE3 gene. Tumors with different specific gene fusions may have different clinicopathological manifestations. Fewer than 10 renal cell carcinoma cases with NONO-TFE3 have been described. Here we examined eight additional cases of this rare tumor using clinicopathological, immunohistochemical, and molecular analyses. The male-to-female ratio of our study cohort was 1:1, and the median age was 30 years...
December 9, 2016: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/27928858/carcinoma-of-the-lower-uterine-segment-diagnosed-with-lynch-syndrome-based-on-msh6-germline-mutation-a-case-report
#20
Masataka Adachi, Kouji Banno, Kenta Masuda, Megumi Yanokura, Moito Iijima, Takashi Takeda, Haruko Kunitomi, Yusuke Kobayashi, Wataru Yamagami, Akira Hirasawa, Kaori Kameyama, Kokichi Sugano, Daisuke Aoki
Endometrial cancer in the lower uterine segment (LUS) is associated with Lynch syndrome with MLH1 or MSH2 germline mutation. Here, we report a case of carcinoma of the LUS diagnosed with Lynch syndrome based on MSH6 germline mutation in a 46-year-old woman with abnormal vaginal bleeding. She had had rectal cancer at age 39 with a family history of colon cancer (father, 75 years), pancreatic cancer (paternal grandmother, 74 years), and colon cancer (maternal grandmother, 85 years). Magnetic resonance imaging showed a tumor in the LUS...
December 8, 2016: Journal of Obstetrics and Gynaecology Research
keyword
keyword
95674
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"